share_log

Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17

Benzinga ·  Aug 9, 2023 12:12

Piper Sandler analyst David Amsellem downgrades Eagle Pharmaceuticals (NASDAQ:EGRX) from Neutral to Underweight and lowers the price target from $26 to $17.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment